Business Segments:^[1]
a) Biosimilars (60% in FY26 vs 58% in FY25):^[2]
Biocon Biologics Ltd develops and markets
a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology,
and other non-communicable diseases.
It is one of the top 5 global players
in biosimilars and among the top 3
in insulins. It ranks in the top 15
companies worldwide for biomanufacturing capacity and has a presence in ~120+
countries, including the U.S., Europe, and emerging markets. Its product portfolio
includes 10 approved biosimilars and
10 under development.^[3]
b) Research Services (22% in FY26 vs 23% in FY25):^[4]
Syngene is a global CRDMO (Contract Research, Development, and Manufacturing Organization) offering integrated services across pharma, biotech, nutrition, and animal health sectors.
It operates with a team of 5,700+ scientists
including 7% PHDs and serves 400+ active clients, 16 of which are among the top 20
global pharma companies.
c) Generics (18% in FY26 vs 19% in FY25):
Biocon is a global generics player with
vertically integrated operations across
APIs and complex formulations. It was
the first globally to get approval for a
generic GLP-1 drug in the regulated
market. It has a portfolio of 79 APIs
and 83 generic formulations (22
launched in the US). It is advancing
into injectables and peptides for
oncology, diabetes, and obesity. ^[5]
d) Novel Biologics:
Biocon's novel biologics portfolio includes Itolizumab, an anti-CD6 antibody launched
for psoriasis in India. Bicara Therapeutics,
an associate based in the US, develops bifunctional antibodies that leverage
immuno-oncology advancements. ^[6]